Published by Unseen Progress, an independent publisher of caregiver research. Last reviewed 2026-05-10. Part of the reactive dog research overview.
Short answer. Behavioural medications — most commonly fluoxetine (a daily SSRI) and trazodone (a situational-use serotonin modulator) — are appropriate when a dog's baseline arousal or anxiety is high enough that under-threshold training is consistently impossible without pharmacological support. They are adjuncts, not substitutes, for behaviour modification (Crowell-Davis et al., 2019; Overall, 2013). Used correctly, they lower the floor enough that counter-conditioning work can land. Used as a replacement for training, they fail.
The clinical literature on canine behaviour pharmacology is consistent on one point: medication is most useful when it lowers the dog's baseline state enough that the behaviour-modification work — counter-conditioning, threshold management, structured set-ups — can actually take hold (Crowell-Davis et al., 2019; Overall, 2013; Mills et al., 2013). On its own, medication does not change the dog's emotional response to triggers. With behaviour modification running in parallel, it can dramatically accelerate the work in cases where baseline anxiety would otherwise keep the dog over threshold no matter what the handler does.
Karen Overall (2013) frames it directly: in cases of generalised anxiety, panic disorder, or sound phobia, the dog cannot learn until the underlying state is medicated. Treating the case as "training only" in that population is the equivalent of treating clinical depression with productivity tips.
Fluoxetine (a selective serotonin reuptake inhibitor, sold under brands including Reconcile and Prozac) is the most widely-prescribed behavioural medication for dogs in North America (Crowell-Davis et al., 2019). The mechanism: it raises synaptic serotonin levels gradually over weeks, reducing baseline anxiety, panic, and reactivity in dogs whose underlying state is anxiety-driven.
Key features in the clinical literature:
Fluoxetine is most strongly indicated when the case meets two criteria: anxiety is generalised or clearly mediating the reactivity, and behaviour-modification work has plateaued or cannot get started because baseline arousal is too high.
Trazodone (a serotonin antagonist and reuptake inhibitor, SARI) is used for situational anxiety — vet visits, fireworks, thunderstorms, predictable trigger events — and as a short-term adjunct during the early weeks of behaviour-modification work in highly aroused dogs (Crowell-Davis et al., 2019; Gilbert-Gregory et al., 2016).
Key features:
Trazodone is especially useful in two scenarios for reactive dogs: (1) a known stressor period such as fireworks season or a planned move, and (2) the early weeks of a behaviour-modification protocol when the dog is still too aroused for under-threshold work.
The veterinary psychopharmacology literature also describes:
The choice between these is the veterinarian's or behaviourist's call — based on the case, comorbidities, and prior medication response.
Drawing across Crowell-Davis et al. (2019), Overall (2013), and ACVB practitioner guidance, the typical indications for behavioural medication in a reactive dog are:
1. Generalised anxiety pattern — fear across many unrelated contexts, not just walk triggers 2. Severe baseline arousal — the dog is consistently over threshold even at large distances or in quiet environments 3. Plateaued behaviour modification — 3–6 months of consistent reward-based work with no measurable progress 4. Comorbid sound phobia, separation anxiety, or panic patterns 5. Predictable high-stress periods — fireworks season, planned travel, household changes 6. Severe reactivity that prevents the dog accessing necessary care — vet visits, grooming
Medication is contraindicated as a replacement for behaviour modification (Overall, 2013). Cases where this is the failure mode:
The Crowell-Davis text and the AVSAB practitioner literature both emphasise that medication is one variable in a multi-variable system; expecting it to be the single intervention that fixes a complex behavioural case is the most common reason owners report disappointment.
The clinically standard sequence (Overall, 2013; ACVB):
1. Veterinary behaviourist (or behaviour-trained primary vet) evaluates case 2. Medical workup rules out pain and endocrine contributors 3. Diagnosis assigned (generalised anxiety, situational fear, panic disorder, etc.) 4. Medication initiated alongside a designed behaviour-modification protocol 5. 4–8 week follow-up to assess response and side effects 6. Protocol adjusted; behaviour modification continues 7. After 6–12 months of stable progress, taper considered if appropriate
---
Unseen Progress publishes long-form caregiver research and builds research-backed daily trackers for the families covered. See the full reactive dog research overview for the complete framework.